Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE 株式レポート

時価総額:₹1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Lotus Eye Hospital and Institute 過去の業績

過去 基準チェック /26

Lotus Eye Hospital and Instituteは、平均年間31.6%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間31.6% 6.4%収益成長率で 成長しています。 Lotus Eye Hospital and Instituteの自己資本利益率は4.9%であり、純利益率は6%です。

主要情報

26.8%

収益成長率

27.2%

EPS成長率

Healthcare 業界の成長29.4%
収益成長率7.0%
株主資本利益率3.6%
ネット・マージン4.4%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

収支内訳

Lotus Eye Hospital and Institute の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:LOTUSEYE 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Jun 2448522350
31 Mar 2448229350
31 Dec 2348535340
30 Sep 2348640340
30 Jun 234774100
31 Mar 2347041340
31 Dec 2246440310
30 Sep 2245942310
30 Jun 224494600
31 Mar 2238930320
31 Dec 2138936230
30 Sep 2137232230
30 Jun 213352000
31 Mar 2132416230
31 Dec 20300-5360
30 Sep 20301-14360
30 Jun 20335-600
31 Mar 2040611360
31 Dec 1942021300
30 Sep 1941520300
30 Jun 194011100
31 Mar 193847350
31 Dec 183827320
30 Sep 183819320
30 Jun 183841400
31 Mar 1838017310
31 Dec 173738290
30 Sep 173594290
30 Jun 17350600
31 Mar 173404290
31 Dec 163307270
30 Sep 163247270
30 Jun 16314000
31 Mar 163111270
31 Dec 15311-5510
30 Sep 15315-6510
30 Jun 15308-14510
31 Mar 15302-20310
31 Dec 14298-12410
30 Sep 14290-9410
30 Jun 142891410
31 Mar 142880410
31 Dec 132874370

質の高い収益: LOTUSEYEは 高品質の収益 を持っています。

利益率の向上: LOTUSEYEの現在の純利益率 (6%)は、昨年(8.7%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: LOTUSEYEの収益は過去 5 年間で年間31.6%増加しました。

成長の加速: LOTUSEYEは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: LOTUSEYEは過去 1 年間で収益成長率がマイナス ( -28.5% ) となったため、 Healthcare業界平均 ( 25.6% ) と比較することが困難です。


株主資本利益率

高いROE: LOTUSEYEの 自己資本利益率 ( 4.9% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘